These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24992528)

  • 41. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
    Qi Y; Jo S; Im W
    Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
    Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
    J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
    Soto C; Ofek G; Joyce MG; Zhang B; McKee K; Longo NS; Yang Y; Huang J; Parks R; Eudailey J; Lloyd KE; Alam SM; Haynes BF; ; Mullikin JC; Connors M; Mascola JR; Shapiro L; Kwong PD
    PLoS One; 2016; 11(6):e0157409. PubMed ID: 27299673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.
    Acharya P; Luongo TS; Georgiev IS; Matz J; Schmidt SD; Louder MK; Kessler P; Yang Y; McKee K; O'Dell S; Chen L; Baty D; Chames P; Martin L; Mascola JR; Kwong PD
    J Virol; 2013 Sep; 87(18):10173-81. PubMed ID: 23843638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
    PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody responses to the HIV-1 envelope high mannose patch.
    Daniels CN; Saunders KO
    Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J; Wyatt RT
    PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization.
    Apellániz B; Rujas E; Carravilla P; Requejo-Isidro J; Huarte N; Domene C; Nieva JL
    J Virol; 2014 Nov; 88(22):13367-77. PubMed ID: 25210180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
    Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
    EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.
    Blattner C; Lee JH; Sliepen K; Derking R; Falkowska E; de la Peña AT; Cupo A; Julien JP; van Gils M; Lee PS; Peng W; Paulson JC; Poignard P; Burton DR; Moore JP; Sanders RW; Wilson IA; Ward AB
    Immunity; 2014 May; 40(5):669-80. PubMed ID: 24768348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface.
    Rujas E; Caaveiro JM; Partida-Hanon A; Gulzar N; Morante K; Apellániz B; García-Porras M; Bruix M; Tsumoto K; Scott JK; Jiménez MÁ; Nieva JL
    Sci Rep; 2016 Dec; 6():38177. PubMed ID: 27905530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing Antibodies Targeting HIV-1 gp41.
    Caillat C; Guilligay D; Sulbaran G; Weissenhorn W
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33114242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.
    Lai RP; Yan J; Heeney J; McClure MO; Göttlinger H; Luban J; Pizzato M
    PLoS Pathog; 2011 Dec; 7(12):e1002442. PubMed ID: 22194689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
    Pancera M; Zhou T; Druz A; Georgiev IS; Soto C; Gorman J; Huang J; Acharya P; Chuang GY; Ofek G; Stewart-Jones GB; Stuckey J; Bailer RT; Joyce MG; Louder MK; Tumba N; Yang Y; Zhang B; Cohen MS; Haynes BF; Mascola JR; Morris L; Munro JB; Blanchard SC; Mothes W; Connors M; Kwong PD
    Nature; 2014 Oct; 514(7523):455-61. PubMed ID: 25296255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.
    Wang P; Yang X
    J Virol; 2010 Jul; 84(14):7114-23. PubMed ID: 20463081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
    Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
    Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.